Taking people in EgyptPhase 3
Effect of Some Drugs on Liver Fibrosis
Key facts
- Who runs it
- Sherief Abd-Elsalam
- Where
- Tanta, EgyptSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 45 people, planned
- Started
- 1 Oct 2018
- Expected to end
- Nov 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Candesartan
- Ramipril
- Record updated
- 10 December 2018
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- chronic hepatitis C
Who cannot take part
- Acute hepatitis
- Thalassemia
Where in Egypt
- Sherief Abd-ElsalamTanta, EgyptContact: Abeer Abd-Almohsen, MscTaking people
About the trial
What the trial wants to find out
Effect of Some Drugs on Liver Fibrosis
The 3 groups in the trial
- Control groupNo study treatment, for comparison
No intervention
- CandesartanExisting treatment, for comparison
Candesartan 8 mg/day
- RamiprilExisting treatment, for comparison
Ramipril 1.25 mg/day
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C
- Record updated
- 10 December 2018